article thumbnail

Biopharma M&A in 2024 β€” Five Considerations for Deal Execution

Vantage Partners

Analysis from EY found that life sciences M&A spend was up 34% last year relative to 2022, despite a reduction in deal volume. It’s no great secret that M&A activity in bipoharma has been on the rise over the past 12 months.

article thumbnail

Alliance Launch: The First Hundred Days

Vantage Partners

Over the course of our 25 years in the business, we've realized that when a life sciences company launches a complex alliance, the plan tends to gravitate towards two simultaneous paths: one focused on getting the work done and achieving specific milestones, and the other focused on setting things up (e.g.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Alliance Launch: The First Hundred Days

Vantage Partners

We’ve identified a number of deliverables that typically must be created in the first 100 days of a life sciences alliance launch.

article thumbnail

Virtual Alliance Launch Best Practices

Vantage Partners

This past year, alliance launches across the life sciences industry shifted from in-person to completely virtual.

article thumbnail

Reflections on 2020 ASAP BioPharma Conference: The right mindset is more important than ever

Vantage Partners

In case you missed them during the conference, Stu Kliman and Ben Siddall led a session on β€œEnhancing Partnerships between Life Sciences and Digital Organizations” and Mai-Tal Kennedy moderated a panel with Petra Sansom, Jay Vora, and Vin Sharma about β€œMaking a Positive Impact on New Drug Modality Alliances.”.